Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of …

The use of fibrates in the treatment of dyslipidaemia has changed significantly over recent
years. Their role appeared clear at the start of this century. The Helsinki Heart Study and …

Although less clinical intervention studies have been performed with fibrates than with
statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events …

At a time when the lipid management guidelines give more and more emphasis to the
identification and treatment of high-risk patients with the metabolic syndrome and diabetes …

The metabolic syndrome and type 2 diabetes mellitus are both becoming more prevalent,
and both increase the risk of cardiovascular disease. Many patients are not receiving …

Clinical guidelines highlight the importance of dyslipidaemia management for reducing the
risk of cardiovascular disease in patients with type 2 diabetes and metabolic syndrome …

In the metabolic syndrome and type 2 diabetes, excess energy intake on the background of
genetic predisposition and lifestyle factors leads to the dysregulation of fatty acid metabolism …

Type 2 diabetes mellitus and the closely related metabolic syndrome are associated with
significant risk for cardiovascular disease. Recent evidence suggests that both conditions …

The outcomes of fibrate trials have varied: positive with gemfibrozil in the primary prevention
Helsinki Heart Study and the secondary prevention VA-HIT trial; positive with reservations in …

Evidence of the effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins) within continuum of atherothrombotic conditions and particularly in the treatment …